DaVita (STU:TRL) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:TRL DaVita Inc STU:TRL
86 GF Score
Price €206.40
GF Value €153.07
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is DaVita Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

STU:TRL
86GF Score
DaVita Inc STU:TRL
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is DaVita (STU:TRL) Overvalued in 2026?

Based on GuruFocus' analysis, DaVita stock appears to be overvalued. The current stock price of €206.40 is trading 34.8% above its estimated GF Value™ of €153.07. GuruFocus considers DaVita to be Significantly Overvalued.

Key valuation signals for STU:TRL:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €153.07 vs. price of €206.40 (34.8% above fair value)
  • GF Score™: 86/100 with 6 warning signs

No single metric tells the full story. See the STU:TRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DaVita Business Description

Address 2000 16th Street, Denver, CO, USA, 80202
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
86GF Score

Get the complete analysis for STU:TRL

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€206.40
Price
€153.07
GF Value